Etiology of OHSS and use of dopamine agonists

Fertility and Sterility

Volumn 97, Issue 3, 2012, Pages 517-522

  Soares, Sérgio Reis ^a  

^a INSTITUTO VALENCIANO DE INFERTILIDAD   (Portugal)

Author keywords

dopamine agonists; OHSS; ovarian stimulation; vascular permeability; VEGF

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CHORIONIC GONADOTROPIN; DOPAMINE; GANIRELIX; MESSENGER RNA; PROGESTERONE; QUINAGOLIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CONSTIPATION; DIZZINESS; DRUG WITHDRAWAL; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; NAUSEA AND VOMITING; NONHUMAN; OOCYTE; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SOMNOLENCE;

EID: 84857790761     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2011.12.046     Document Type: Article

References (75)

1. N.F. Vlahos, and O. Gregoriou Prevention and management of ovarian hyperstimulation syndrome Ann N Y Acad Sci 1092 2006 247 264
2. L.C. Grossman, K.G. Michalakis, H. Browne, M.D. Payson, and J.H. Segars The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome Fertil Steril 94 2010 1392 1398
3. R. Gómez, C. Simon, J. Remohi, and A. Pellicer Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade Endocrinology 143 2002 4339 4348
4. B. Rizk, M. Aboulghar, J. Smitz, and R. Ron-El The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome Hum Reprod Update 3 1997 255 266
5. R. Gómez, C. Simón, J. Remohí, and A. Pellicer Administration of moderate and high doses of gonadotrophins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability Biol Reprod 68 2003 2164 2171
6. B.R. Kamat, L.F. Brown, E.J. Manseau, D.R. Senger, and H.F. Dvorak Expression of vascular permeability factor/vascular endothelial growth factor by human granulose and theca lutein cells. Role in corpus luteum development Am J Pathol 146 1995 157 165
7. R.D. Koos, and C.E. Olson Hypoxia stimulates expression of the gene for vascular endothelial growth factor (VEGF), a putative angiogenic factor, by granulosa cells of the ovarian follicle, a site of angiogenesis J Cell Biol 115 1991 421a
8. Z. Yan, H.A. Weich, W. Bernart, M. Breckwoldt, and J. Neulen Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro J Clin Endocrinol Metab 77 1993 1723 1725
9. J. Neulen, Z. Yan, S. Raczek, K. Weindel, C. Keck, and H.A. Weich Human chorionic gonadotrophin-dependent expression of vascular endothelial growth factor/VP factor in human granulosa cells: importance in ovarian hyperstimulation syndrome J Clin Endocrinol Metab 80 1995 1967 1971
10. S. Yamamoto, I. Konishi, Y. Tsuruta, K. Nanbu, M. Mandai, and H. Kuroda Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary Gynecol Endocrinol 11 1997 371 381
11. A. Pellicer, C. Albert, A. Mercader, F. Bonilla-Musoles, J. Remohi, and C. Simon The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor Fertil Steril 71 1999 482 489
12. T.H. Wang, S.G. Horng, C.L. Chang, H.M. Wu, Y.J. Tsai, and H.S. Wang Human chorionic gonadotrophin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor J Clin Endocrinol Metab 87 2002 3300 3308
13. C. Albert, N. Garrido, A. Mercader, C.V. Rao, J. Remohí, and C. Simón The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome Mol Hum Reprod 8 2002 409 418
14. P.J. Keck, S.D. Hauser, G. Krivi, K. Sanzo, T. Warren, and J. Feder Vascular permeability factor, an endothelial cell mitogen related to PDGF Science 246 1989 1309 1312
15. D.W. Leung, G. Cachianes, W.J. Kuang, D.V. Goeddel, and N. Ferrara Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306 1309
16. H.S. Phillips, J. Hains, D.W. Leung, and N. Ferrara Vascular endothelial growth factor is expressed in rat corpus luteum Endocrinology 127 1990 965 967
17. J. Waltenberger, L. Claesson-Welsh, A. Siegbahn, M. Shibuya, and C.H. Heldin Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor J Biol Chem 269 1994 26988 26995
18. H. Gille, J. Kowalski, B. Li, J. LeCouter, B. Moffat, and T.F. Zioncheck Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants J Biol Chem 276 2001 3222 3230
19. D.O. Bates, and S.J. Harper Regulation of vascular permeability by vascular endothelial growth factors Vascul Pharmacol 39 2002 225 237
20. D.O. Bates, N.J. Hillman, B. Williams, C.R. Neal, and T.M. Pocock Regulation of microvascular permeability by vascular endothelial growth factors J Anat 200 2002 581 597
21. D. Guo, Q. Jia, H.Y. Song, S.R. Warren, and D.B. Donner Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediator of signal transduction that contains SH2 domains. Association with endothelial cell proliferation J Biol Chem 270 1995 6729 6733
22. N. McClure, D.L. Healy, P.A. Rogers, J. Sullivan, L. Beaton, and R.V. Haning Jr. Vascular endothelial cell growth factor as permeability agent in ovarian hyperstimulation syndrome Lancet 344 1994 235 236
23. E.R. Levin, G.F. Rosen, D.L. Cassidenti, B. Yee, D. Meldrum, and A. Wisot Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome J Clin Invest 102 1998 1978 1985
24. Y. Abramov, V. Barak, B. Nisman, and J.G. Schenker Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome Fertil Steril 67 1997 261 265
25. R. Agrawal, S.L. Tan, S. Wild, P. Sladkevicius, L. Engmann, and N. Payne Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome Fertil Steril 71 1999 287 293
26. C.D. Chen, M.Y. Wu, H.F. Chen, S.U. Chen, H.N. Ho, and Y.S. Yang Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome Fertil Steril 72 1999 286 292
27. B.C. Kuenen, J. Tabernero, J. Baselga, F. Cavalli, E. Pfanner, and P.F. Conte Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma Clin Cancer Res 9 2003 1648 1655
28. J. Glade-Bender, J.J. Kandel, and D.J. Yamashiro VEGF blocking therapy in the treatment of cancer Expert Opin Biol Ther 3 2003 263 276
29. C. Wulff, H. Wilson, J.S. Rudge, S.J. Wiegand, S.F. Lunn, and H.M. Fraser Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap (A40) J Clin Endocrinol Metab 86 2001 3377 3386
30. R.C. Zimmermann, T. Hartman, P. Bohlen, M.V. Sauer, and J. Kitajewski Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea Microvasc Res 62 2001 15 25
31. R.C. Zimmermann, E. Xiao, N. Husami, M.V. Sauer, R. Lobo, and J. Kitajewski Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey J Clin Endocrinol Metab 86 2001 768 772
32. R.C. Zimmermann, T. Hartman, S. Kavic, S.A. Pauli, P. Bohlen, and M.V. Sauer Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotrophin-dependent follicle development J Clin Invest 112 2003 659 669
33. L.C. Rockwell, S. Pillai, C.E. Olson, and R.D. Koos Inhibition of vascular endothelial growth factor/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents Biol Reprod 67 2002 1804 1810
34. B. Heryanto, K.E. Lipson, and P.A. Rogers Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse Reproduction 125 2003 337 346
35. S.A. Pauli, H. Tang, J. Wang, P. Bohlen, R. Posser, and T. Hartman The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent Endocrinology 146 2005 1301 1311
36. A.P. Ferraretti, L. Gianaroli, L. Diotallevi, C. Festi, and A.O. Trounson Dopamine treatment for severe ovarian hyperstimulation syndrome Hum Reprod 7 1992 180 183
37. T. Tsunoda, H. Shibahara, Y. Hirano, T. Suzuki, H. Fujiwara, and S. Takamizawa Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine Gynecol Endocrinol 17 2003 281 286
38. E. Papaleo, N. Doldi, L. De Santis, G. Marelli, E. Marsiglio, and S. Rofena Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome Hum Reprod 16 2001 2263 2266
39. D. Eljarmak, M. Lis, M. Cantin, P.D. Carriere, and R. Collu Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma Horm Res 21 1985 160 167
40. S. Basu, and P.S. Dasgupta Alteration of dopamine D2 receptors in human malignant stomach tissue Dig Dis Sci 42 1997 1260 1264
41. S. Basu, C. Sarkar, D. Chakroborty, J. Nagy, R.B. Mitra, and P.S. Dasgupta Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis Cancer Res 64 2004 5551 5555
42. S. Basu, J.A. Nagy, S. Pal, E. Vasile, I.A. Eckelhoefer, and V.S. Bliss The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor Nat Med 7 2001 569 574
43. M. Manno, F. Tomei, E. Marchesan, and V. Adamo Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 122 2005 127 128
44. J. Gerris, A. Delvigne, and F. Oliveness Ovarian hyperstimulation syndrome 1st ed. 2006 Informa Healthcare London 131-48
45. M.C. Shelesnyak Disturbance of hormone balance in the female rat by a single injection of ergotoxine ethanesulphonate Am J Physiol 180 1955 47 49
46. G.P. Mueller, J. Simpkins, J. Meites, and K.E. Moore Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats Neuroendocrinology 20 1976 121 135
47. R. Mornex, J. Orgiazzi, B. Hugues, J.C. Gagnaire, and B. Claustrat Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors J Clin Endocrinol Metab 47 1978 290 295
48. M. Bigazzi, R. Ronga, I. Lancranjan, S. Ferraro, F. Branconi, and P. Buzzoni A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments J Clin Endocrinol Metab 48 1979 9 12
49. E. Robert, L. Musatti, G. Piscitelli, and C.I. Ferrari Pregnancy outcome after treatment with the ergot derivative, cabergoline Reprod Toxicol 10 1996 333 337
50. E. Ciccarelli, S. Grottoli, P. Razzore, D. Gaia, A. Bertagna, and S. Cirillo Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy J Endocrinol Invest 20 1997 547 551
51. C. Liu, and J.B. Tyrrell Successful treatment of a large macroprolactinoma with cabergoline during pregnancy Pituitary 4 2001 179 185
52. R. Gómez, M. González-Izquierdo, R.C. Zimmermann, E. Novella-Maestre, I. Alonso-Muriel, and J. Sanchez-Criado Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model Endocrinology 147 2006 5400 5411
53. C.V. Parast, B. Mroczkowski, C. Pinko, S. Misialek, G. Khambatta, and K. Appelt Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR-2 TK), a key enzyme in angiogenesis Biochemistry 37 1998 16788 16801
54. C. Cristina, G. Díaz-Torga, A. Baldi, A. Góngora, M. Rubinstein, and M.J. Low Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice Endocrinology 146 2005 2952 2962
55. R. Gómez, H. Ferrero, F. Delgado-Rosas, M. Gaytan, C. Morales, and R.C. Zimmermann Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment J Clin Endocrinol Metab 96 2011 2484 2492
56. B.R. Kamat, L.F. Brown, E.J. Manseau, D.R. Senger, and H.F. Dvorak Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development Am J Pathol 146 1995 157 165
57. F. Delgado-Rosas, M. Gaytán, C. Morales, R. Gómez, and F. Gaytán Superficial ovarian cortex vascularization is inversely related to the follicle reserve in normal cycling ovaries and is increased in polycystic ovary syndrome Hum Reprod 24 2009 1142 1151
58. C. Álvarez, L. Martí-Bonmatí, E. Novella-Maestre, R. Sanz, R. Gómez, and M. Fernández-Sánchez Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction J Clin Endocrinol Metab 92 2007 2931 2937
59. J.A. Vanrell, and J. Balasch Prolactin in the evaluation of luteal phase in infertility Fertil Steril 39 1983 30 33
60. C. Álvarez, I. Alonso-Muriel, G. García, J. Crespo, J. Bellver, and C. Simón Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome (OHSS) in women undergoing ART: a pilot study Hum Reprod 22 2007 3210 3214
61. E. Ricci, F. Parazzini, T. Motta, C.I. Ferrari, A. Colao, and A. Clavenna Pregnancy outcome after cabergoline treatment in early weeks of gestation Reprod Toxicol 16 2002 791 793
62. C. Carizza, V. Abdelmassih, S. Abdelmassih, P. Ravizzini, L. Salgueiro, and P.T. Salgueiro Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study Reprod Biomed Online 17 2008 751 755
63. M.A.F.M. Youssef, M. van Wely, M.A. Hassan, H.G. Al-Inany, M. Mochtar, and S. Khattab Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis Hum Reprod Update 16 2010 459 466
64. Salah Edeen AMR, Alhelou YM. Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Abstracts of the 25th Annual Meeting of ESHRE, Amsterdam, the Netherlands, 28 June-1 July 2009.
65. Shaltout A, Shohayeb A, Eid M, Abbas S. Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Abstracts of the 25th Annual Meeting of ESHRE, Amsterdam, the Netherlands, 28 June-1 July 2009.
66. A. Antonini, and W. Poewe Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease Lancet Neurol 6 2007 826 829
67. M. Kars, V. Delgade, E.R. Holman, R.A. Feelders, J.W.A. Smit, and J.A. Romijn Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma J Clin Endocrinol Metab 93 2008 3348 3356
68. N.M. Martin, T. Tan, and K. Meeran Dopamine agonists and hyperprolactinaemia Br Med J 338 2009 554 555
69. B.L. Roth Drugs and valvular heart disease N Engl J Med 356 2007 6 7
70. R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, and G. Pezzoli Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med 356 2007 39 46
71. C. Busso, M. Fernández-Sánchez, J.A. García-Velasco, J. Landeras, A. Ballesteros, and E. Muñoz The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial Hum Reprod 25 2010 995 1004
72. V. Sherwal, S. Malik, and V. Bhatia Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction J Hum Reprod Sci 3 2010 85 90
73. D. Spitzer, J. Wogatzky, M. Murtinger, M.H. Zech, R. Haidbauer, and N.H. Zech Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome Fertil Steril 95 2011 2742 2744
74. B. Ata, A. Seyhan, S. Orhaner, and B. Urman High dose cabergoline in management of ovarian hyperstimulation syndrome Fertil Steril 92 2009 1168.e1 1168.e4
75. N. Rollene, M.H. Amols, S.B.A. Hudson, and C.C. Coddington Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and a gonadotropin releasing-hormone antagonist: a case series Fertil Steril 92 2009 1169.e15 1169.e17